News and updates

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System (ICS) leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.

This report provides a medicines roadmap to support the uptake and implementation of electronic repeat dispensing (eRD). It also presents the results of an analysis on the impact of high levels of eRD implementation on prescribing volume and hospital admissions.

The eRD medicines roadmap strategic insight report can be accessed here

Pharmacogenomics (PGx) is a key component of personalised medicine. The purpose of this bulletin is to introduce PGx to medicines committees and working groups and provide considerations for embedding PGx testing into medicines governance structures and processes, supporting the safe and effective use of medicines.

This document was updated on 5th of February 2026 with minor text revisions to improve clarity. 

This publication is open access.

Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in December 2025:

• Monthly formulary amendments – December 2025
• Monthly horizon scanning – January 2026

This document compares the ciclosporin eye drops licensed in the UK for use in adults. It is intended as a quick reference to summarise differences between the available preparations.

The comparison document for ciclosporin eye drops can be found here

The RDTC Annual Horizon Scanning report is now available here.

Each year the RDTC considers the information published in the SPS Prescribing Outlook series, and from this information highlights developments that are likely to have significant impact on primary care prescribing budgets, over the coming 12 – 15 months.

This is supplemented throughout the year with the RDTC Monthly Horizon Scanning series, which provides an account of new medicines and recommendations as they publish. This is available from the RDTC website.

The RDTC Annual Horizon Scanning report highlights relevant national guidance and policies, expected cost pressures, and anticipated risks.

The aim of this publication is to evaluate the efficacy, safety and potential place in therapy of Clascoterone cream a first-in-class androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

The new drug evaluation for clascoterone can be accessed here

Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour. This document aims to review the evidence base for the use of docusate in the management of constipation, and discusses the over prescribing of laxatives in general.

The Medicines in Practice bulletin on docusate can be accessed here